RMC-9805 is an investigational medication being studied for treating non-small cell lung cancer (NSCLC) in patients with specific RAS G12D mutations. This is a new drug that targets specific genetic changes in cancer cells.

RMC-6236 is another investigational medication that works together with RMC-9805 to treat non-small cell lung cancer. It is being tested to see if the combination provides better results for patients with RAS G12D mutations.

Pembrolizumab is an immunotherapy medication that helps the body’s immune system fight cancer cells. It works by blocking certain proteins that can prevent immune cells from attacking cancer.

The trial also includes chemotherapy medications that are commonly used to treat cancer by killing rapidly dividing cells. These medications are used in combination with the other treatments mentioned above.

Lung Cancer – A disease that begins in the lungs when cells grow out of control and form tumors. It typically starts in the cells lining the bronchi and parts of the lung such as the bronchioles or alveoli. The abnormal cells continue to grow and can spread to nearby tissues or other parts of the body. Lung cancer often develops slowly over many years, with changes occurring in the lung tissue before actual tumors form. Early in the disease, people may not notice any symptoms as the changes are happening at a cellular level. As the disease progresses, it can cause breathing difficulties, persistent cough, and changes in breathing patterns.